* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BM8 vs CYTK, ARWR, TECH: Days Payable Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Days Payable distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioMarin Pharmaceutical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (HAM:BM8) has a Days Payable of 164.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioMarin Pharmaceutical and its competitors. This is near median its historical median of 180.41. Over the past decade, BioMarin Pharmaceutical's Days Payable has ranged from 139.44 to 322.69. According to the industry distribution chart, BioMarin Pharmaceutical ranks #286 out of 700 companies in the Biotechnology industry, placing it in the top 40.9%.
Is BioMarin Pharmaceutical's Days Payable too high?
BioMarin Pharmaceutical's current Days Payable of 164.78 is near median its 10-year median of 180.41. Over the past 10 years, this metric has ranged from a low of 139.44 to a high of 322.69. The Biotechnology industry median Days Payable is 113.10. BioMarin Pharmaceutical's value of 164.78 is 45.7% above this industry median. Based on the distribution chart, BioMarin Pharmaceutical ranks #286 out of 700 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioMarin Pharmaceutical has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Days Payable compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #286 out of 700 companies for Days Payable. This puts BioMarin Pharmaceutical in the upper half of its industry. The industry median Days Payable is 113.10. BioMarin Pharmaceutical's value of 164.78 is 45.7% above this benchmark. Historically, BioMarin Pharmaceutical's own Days Payable has ranged from 139.44 to 322.69 over the past decade. While the company's 10-year median is 180.41 vs. the industry median of 113.10, BioMarin Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMarin Pharmaceutical's current Days Payable of 164.78 is 45.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioMarin Pharmaceutical and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMarin Pharmaceutical's current Days Payable is 164.78, which is near median its own 10-year median of 180.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current Days Payable of 164.78. The stock's GF Value™ is €77.58, compared to a current price of €51.94 — trading 33% below its estimated fair value. The current Days Payable is 164.78, which is near median its 10-year median of 180.41 and 45.7% above the Biotechnology industry median of 113.10. BioMarin Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current Days Payable is 164.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of €51.94 is trading 33% below its estimated GF Value™ of €77.58.
Key valuation signals for HAM:BM8:
Days Payable: 164.78 (near median its 10-year median of 180.41)
GF Value™: €77.58 vs. price of €51.94 (33% below fair value)
Industry Position: 45.7% above the Biotechnology median (#286 of 700)
No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score
Get the complete analysis for HAM:BM8
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BM8 has been successfully added to your 
